ArticleClinical breast cancer2022

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.

Rami S Vanguri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.